WHC is still in active development. Read this to understand our approach.
depiction of ZSTKHSQDNIGFLM-UHFFFAOYSA-N.svg
tripsit

5-meo-dmt

Verificar en tripsit

psychonaut

5-MeO-DMT

Verificar en psychonaut

isomerdesign

5-MeO-DMT

Verificar en isomerdesign

druglab

5-MeO-DMT

Verificar en druglab

drugmap

5-MEO-DMT

Verificar en drugmap

wiki

5-MeO-DMT

Verificar en wiki

Data

InChI: InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3

Sinónimos: N,N-Dimethyl-5-methoxytryptamine,Maybridge3_000045,3-(2-(N,N-Dimethyl)aminoethyl)-5-methoxyindole,INDOLE, 3-(2-(N,N-DIMETHYLAMINO)ETHYL)-5-METHOXY-, O-Methylbufotenine,2-(5-methoxy-1H-indol-3-yl)ethyl-dimethyl-amine,2-(5-methoxy-1H-indol-3-yl)-ethyl-dimethyl-amine,NCGC00015654-05, INDOLE, 3-(2-(N,N-DIMETHYLAMINO)ETHYL)-5-METHOXY-,Methoxybufotenin,BDBM30707,PDSP1_000032, 5-OMe-DMT,3-[2-(N,N-Dimethylamino)ethyl]-5-methoxyindole,Bufotenine, 5-Methoxydimethyltryptamine,HMS3370M04,019D450,WLN: T56 BMJ D2N1&1 GO1,EINECS 213-813-2,2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine, 5-Methoxy-N,N-dimethyltryptamine,NCGC00015654-06,D-5380,[2-(5-METHOXY-1H-INDOL-3-YL)-ETHYL]-DIMETHYL-AMINE,cid_1832,5-MeO DMT,NCGC00023288-03,L000724,3-(2-Dimethylaminoethyl)-5-methoxyindole,IDI1_011432,Bufotenine, O-methyl-,Lopac0_000724,X0MKX3GWU9, UNII-X0MKX3GWU9,O-Methylbufotenine,NSC 88624,NCGC00015654-01,5-Methoxy-3-[2-(dimethylamino)ethyl]indole,Mebufotenin,DB-005455,NCGC00015654-02,Methylbufotenine, 3-(2-Dimethylaminoethyl)-5-methoxyindole,1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-,MeODMT,CHEBI:2086,2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine #, Methoxydimethyltryptamines,DTXSID70144324,CT 4334, Bufotenine, O-methyl-,mebufotenin [INN],PDSP2_000032,N,N,O-TMS,5-Methoxy-N,N-dimethyl-1H-indole-3-ethanamine,UNII-X0MKX3GWU9, 5-MeO-DMT,2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethan-1-amine, 5-Methoxy-N,N-dimethyl-1H-indole-3-ethanamine,5-MeO-DMT solution, 1.0 mg/mL in methanol, certified reference material,5-22-12-00027 (Beilstein Handbook Reference),SMR000059066,SDCCGMLS-0003129.P003,Indole,N-dimethylamino)ethyl]-5-methoxy-,CHEMBL7257,1019-45-0,MLS000069438,3-(2-(N,N-Dimethylamino)ethyl)-5-methoxyindole,Lopac-M-2381,5-medmt,HMS2235C20,BRN 0164771,5meodmt,C08309,5-meo,5-methoxyindole 3-(2-(N,N-Dimethylamino)ethyl),DB14010,PDSP1_000447,AKOS005203483,Methoxydimethyltryptamines, Methylbufotenine,CCG-204809,3-[2-(N,N-Dimethylamino)ethyl]-5-methoxy-indole,NSC88624, 2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethylethanamine,N,N,O-Trimethylserotonin,NCGC00015654-04,STK368074,N,N-Dimethyl-5-methoxytryptamine, free base,Q570757,2-(5-methoxy-1H-indol-3-yl)-N,N-dimethyl-ethanamine, Methoxybufotenin,Oprea1_596468,Bufotenine methyl ether, MeODMT, 1019-45-0,5-OMe-DMT,Tryptamine, 5-methoxy-N,N-dimethyl,5-Methoxydimethyltryptamine,5-METHOXY-N-DIMETHYLTRYPTAMINE,Bufotenine (O) ME,NCGC00015654-03,5-Methoxy-N,N-dimethyltryptamine, 5-Methoxydimethyltryptamine,5-Methoxy-N,N-dimethyl-1H-indole-3-ethylamine,Indole, 3-[2-(dimethylamino)ethyl]-5-methoxy-,PDSP2_000445,SCHEMBL132733,5meo, NSC 88624,NCGC00023288-04,GTPL145,5-MeO-DMT,NSC-88624, 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-,N,N-Dimethyl-5-methoxy tryptamine,ZINC57152,BRD-K34224286-001-07-1,toads,OMB,Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-, CT 4334,[2-(5-methoxy-1H-indol-3-yl)ethyl]dimethylamine,HMS1431C01,Indole, 5-methoxy-3-[2-(dimethylamino)ethyl]

Market name: 5-meo-dmt

Estimated data

Solubilidad: -1.747 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 88.1% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.